文献速递心脑血管急症重症综合管理与镇静镇痛

癌症合并急性冠脉综合征患者的死亡率、出血和缺血事件预测:模型开发与验证研究

Prediction of mortality, bleeding, and ischaemic events in patients with cancer and acute coronary syndrome: a model development and validation study.
PubMed 文献 · Lancet · 2026-01-01
一句话结论ONCO-ACS评分可预测癌症合并急性冠脉综合征患者6个月全因死亡、大出血和缺血事件,外部验证区分度良好。

该模型开发与验证研究纳入英格兰、瑞典和瑞士2004年1月1日至2023年8月8日期间1 017 759例急性冠脉综合征患者(英格兰815 170例,其中癌症36 771例;瑞典194 059例,其中癌症10 262例;瑞士8 530例,其中癌症203例),基于机器学习在竞争风险框架下开发ONCO-ACS评分,预测6个月全因死亡、大出血和缺血事件。癌症合并急性冠脉综合征患者死亡率高(累积发生率27.8% [95% CI 27.3-28.3])、大出血7.3% [7.0-7.5]、缺血事件16.1% [15.7-16.4]。ONCO-ACS评分在内部验证中6个月全因死亡tAUC为0.84(0.83-0.85),大出血0.70(0.68-0.73),缺血事件0.79(0.78-0.81);外部验证表现相似。该评分校准良好,决策曲线分析提示临床效用良好。

要点

  • 癌症合并急性冠脉综合征患者6个月全因死亡累积发生率27.8%(95% CI 27.3-28.3),大出血7.3%(7.0-7.5),缺血事件16.1%(15.7-16.4)。
  • ONCO-ACS评分由肿瘤类型、癌症诊断后时间、转移性疾病、年龄、血红蛋白、心率、eGFR、BMI、Killip分级、心脏骤停和6个月内大出血共一组变量构成。
  • 内部验证6个月全因死亡tAUC 0.84(0.83-0.85),大出血0.70(0.68-0.73),缺血事件0.79(0.78-0.81)。
  • 外部验证全因死亡tAUC:英格兰中部0.84(0.82-0.85),瑞典0.80(0.79-0.82),瑞士0.83(0.76-0.91)。
  • 将ONCO-ACS应用于现行指南提示,大多数癌症合并急性冠脉综合征患者符合侵入性管理和使用氯吡格雷的长期双联抗血小板治疗。

适用人群与场景

  • 英格兰、瑞典和瑞士2004年1月1日至2023年8月8日期间因急性冠脉综合征就诊的患者,其中癌症患者纳入分析(英格兰36 771例,瑞典10 262例,瑞士203例)。

研究设计与关键结果

  • 研究类型为模型开发与验证研究,纳入英格兰、瑞典和瑞士1 017 759例急性冠脉综合征患者(英格兰815 170例,其中癌症36 771例;瑞典194 059例,其中癌症10 262例;瑞士8 530例,其中癌症203例),开发机器学习模型在竞争风险框架下预测6个月全因死亡、大出血和缺血事件(定义为心血管死亡、心肌梗死和缺血性卒中的复合终点)。
  • 癌症合并急性冠脉综合征患者6个月全因死亡累积发生率27.8%(95% CI 27.3-28.3),大出血7.3%(7.0-7.5),缺血事件16.1%(15.7-16.4)。
  • ONCO-ACS评分变量包括肿瘤类型、癌症诊断后时间、转移性疾病、年龄、血红蛋白、心率、eGFR、BMI、Killip分级、心脏骤停和6个月内大出血。
  • 内部验证6个月tAUC:全因死亡0.84(0.83-0.85),大出血0.70(0.68-0.73),缺血事件0.79(0.78-0.81)。
  • 外部验证全因死亡6个月tAUC:英格兰中部0.84(0.82-0.85),瑞典0.80(0.79-0.82),瑞士0.83(0.76-0.91);大出血:英格兰中部0.70(0.67-0.74),瑞典0.67(0.65-0.70),瑞士0.74(0.57-0.91);缺血事件:英格兰中部0.76(0.74-0.78),瑞典0.70(0.69-0.72),瑞士0.73(0.61-0.86)。
  • ONCO-ACS评分校准良好,决策曲线分析提示临床效用良好;将ONCO-ACS应用于现行指南提示大多数癌症合并急性冠脉综合征患者符合侵入性管理和使用氯吡格雷的长期双联抗血小板治疗。

证据类型、等级与局限

  • 证据类型:模型开发与验证研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • ONCO-ACS评分可用于预测癌症合并急性冠脉综合征患者6个月全因死亡、大出血和缺血事件风险,联合评估竞争结局风险可能有助于权衡治疗获益与危害。
  • 将ONCO-ACS应用于现行指南提示大多数癌症合并急性冠脉综合征患者符合侵入性管理和使用氯吡格雷的长期双联抗血小板治疗。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Accurate assessment of mortality, bleeding, and atherothrombotic risk in patients with cancer and acute coronary syndrome could inform novel personalised treatment strategies, but no standardised tools for this purpose exist. We aimed to develop and validate a clinically applicable risk score for mortality, bleeding, and ischaemic events in patients with cancer and acute coronary syndrome.

METHODS: In this model development and validation study, we obtained data for 1 017 759 patients who presented with acute coronary syndrome in England, UK (n=815 170; 36 771 with cancer), Sweden (n=194 059; 10 262 with cancer), and Switzerland (n=8530; 203 with cancer) between Jan 1, 2004, and Aug 8, 2023. Machine learning models were developed to predict all-cause mortality, major bleeding events, and ischaemic events, defined as a composite of cardiovascular death, myocardial infarction, and ischaemic stroke, in patients with cancer and acute coronary syndrome from England in a competing risks framework with a prediction horizon of 6 months. Final models (the ONCO-ACS score) were externally validated in geographically distinct held out datasets from the English Midlands, Sweden, and Switzerland.

FINDINGS: Patients with cancer and with acute coronary syndrome were characterised by high rates of mortality (cumulative incidence 27·8% [95% CI 27·3-28·3]), major bleeding (7·3% [7·0-7·5]), and ischaemic events (16·1% [15·7-16·4]) and had a distinct risk profile. The ONCO-ACS score was informed by a single set of variables: tumour type, time since cancer diagnosis, metastatic disease, age, haemoglobin, heart rate, estimated glomerular filtration rate, BMI, Killip class, cardiac arrest, and major bleed within 6 months. Accounting for traditional and cancer-related risk factors, ONCO-ACS showed a time-dependent area under the receiver operating characteristic curve (tAUC) at 6 months of 0·84 (0·83-0·85) for all-cause mortality, 0·70 (0·68-0·73) for major bleeding, and 0·79 (0·78-0·81) for ischaemic events on internal validation. On external validation, ONCO-ACS achieved similar performance for all-cause mortality (tAUC at 6 months 0·84 [0·82-0·85] for the English Midlands, 0·80 [0·79-0·82] for Sweden, and 0·83 [0·76-0·91] for Switzerland), major bleeding events (0·70 [0·67-0·74] for the English Midlands, 0·67 [0·65-0·70] for Sweden, and 0·74 [0·57-0·91] for Switzerland), and ischaemic events (0·76 [0·74-0·78] for the English Midlands, 0·70 [0·69-0·72] for Sweden, and 0·73 [0·61-0·86] for Switzerland). ONCO-ACS was well calibrated and decision curve analyses suggested favourable clinical utility. Applying ONCO-ACS to current guidelines suggests that most patients with cancer and acute coronary syndrome qualify for invasive management and long dual antiplatelet therapy using clopidogrel.

INTERPRETATION: The ONCO-ACS score provides a validated practical tool for predicting mortality, bleeding, and ischaemic risk in patients with cancer and acute coronary syndrome. Combined assessment of competing outcome risks could facilitate balancing treatment benefits and harms.

FUNDING: British Heart Foundation, Cancer Research UK, Swiss Heart Foundation, University of Zurich Foundation, Kurt-Senta-Herrmann Foundation, Theodor-Ida-Herzog-Egli Foundation, Foundation for Cardiovascular Research-Zurich Heart House, Swedish ALF Research Funds.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Wenzl FA, Ow KW, Velders MA, et al. Prediction of mortality, bleeding, and ischaemic events in patients with cancer and acute coronary syndrome: a model development and validation study. Lancet. 2026. PMID: 41620233. doi:10.1016/S0140-6736(25)02020-3

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。